Daniel J Friedman1, Chengan Du2, Yongfei Wang3, Vratika Agarwal2, Paul D Varosy4, Frederick A Masoudi5, David R Holmes6, Vivek Y Reddy7, Matthew J Price8, Jeptha P Curtis3, James V Freeman9. 1. Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA; Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA. Electronic address: daniel.friedman@duke.edu. 2. Center for Outcomes Research and Evaluation, Yale New Haven Health, New Haven, Connecticut, USA. 3. Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA; Center for Outcomes Research and Evaluation, Yale New Haven Health, New Haven, Connecticut, USA. 4. Division of Cardiology, University of Colorado School of Medicine, Denver, Colorado, USA; Cardiology Section, VA Eastern Colorado Health Care System, Aurora, Colorado, USA. 5. Division of Cardiology, University of Colorado School of Medicine, Denver, Colorado, USA. 6. Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA. 7. Division of Cardiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 8. Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California, USA. 9. Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA; Center for Outcomes Research and Evaluation, Yale New Haven Health, New Haven, Connecticut, USA. Electronic address: https://twitter.com/JFreeMD.
Abstract
OBJECTIVES: The aim of this study was to compare outcomes among patients from the PROTECT-AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation) and PREVAIL (Evaluation of the WATCHMAN Left Atrial Appendage [LAA] Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy) left atrial appendage occlusion (LAAO) trials with matched patients from the National Cardiovascular Data Registry LAAO Registry using patient-level data. BACKGROUND: Patients undergoing LAAO in clinical practice generally have more comorbidities than trial participants. METHODS: Propensity-matched analyses, with up to 3 registry patients matched to each trial patient, were performed using Cox proportional hazards and Fine-Gray models. RESULTS: A total of 1,904 registry patients were matched to 667 trial LAAO patients; 1,010 registry patients were matched to 348 warfarin patients. Compared with registry patients, trial LAAO patients experienced more pericardial effusion requiring intervention (3.8% vs 0.6%, P < 0.001), periprocedural ischemic stroke (0.9% vs 0.2%, P = 0.005), and failed device implantation (7.5% vs 3.6%, P < 0.001). The 425-day risk of ischemic stroke in trial LAAO patients was higher than in registry patients (2.70% vs 1.21%; HR: 1.951; P = 0.03); warfarin patients had comparable rates of ischemic stroke compared with registry patients (1.15% vs 1.29%; HR: 0.728; P = 0.57). Hemorrhagic stroke risk was similar among trial LAAO and registry patients (P = 0.88). Hemorrhagic stroke risk was greater among warfarin patients versus registry patients (1.44% vs 0.20%; HR: 5.871, P = 0.03). Mortality was lower in trial LAAO patients than in registry patients (2.92% vs 6.23%; HR: 0.477; P = 0.004), a difference attributable to noncardiovascular deaths. Mortality was similar (P = 0.44) among trial warfarin (4.48%) and registry (5.86%) patients. CONCLUSION: In clinical practice, patients who meet trial criteria and undergo LAAO experience a lower risk of ischemic stroke, a similar risk of hemorrhagic stroke, and a higher risk of death after implant versus LAAO trial patients. (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation [PROTECT-AF], NCT00129545; Evaluation of the WATCHMAN Left Atrial Appendage [LAA] Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy [PREVAIL], NCT01182441).
OBJECTIVES: The aim of this study was to compare outcomes among patients from the PROTECT-AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation) and PREVAIL (Evaluation of the WATCHMAN Left Atrial Appendage [LAA] Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy) left atrial appendage occlusion (LAAO) trials with matched patients from the National Cardiovascular Data Registry LAAO Registry using patient-level data. BACKGROUND: Patients undergoing LAAO in clinical practice generally have more comorbidities than trial participants. METHODS: Propensity-matched analyses, with up to 3 registry patients matched to each trial patient, were performed using Cox proportional hazards and Fine-Gray models. RESULTS: A total of 1,904 registry patients were matched to 667 trial LAAO patients; 1,010 registry patients were matched to 348 warfarin patients. Compared with registry patients, trial LAAO patients experienced more pericardial effusion requiring intervention (3.8% vs 0.6%, P < 0.001), periprocedural ischemic stroke (0.9% vs 0.2%, P = 0.005), and failed device implantation (7.5% vs 3.6%, P < 0.001). The 425-day risk of ischemic stroke in trial LAAO patients was higher than in registry patients (2.70% vs 1.21%; HR: 1.951; P = 0.03); warfarin patients had comparable rates of ischemic stroke compared with registry patients (1.15% vs 1.29%; HR: 0.728; P = 0.57). Hemorrhagic stroke risk was similar among trial LAAO and registry patients (P = 0.88). Hemorrhagic stroke risk was greater among warfarin patients versus registry patients (1.44% vs 0.20%; HR: 5.871, P = 0.03). Mortality was lower in trial LAAO patients than in registry patients (2.92% vs 6.23%; HR: 0.477; P = 0.004), a difference attributable to noncardiovascular deaths. Mortality was similar (P = 0.44) among trial warfarin (4.48%) and registry (5.86%) patients. CONCLUSION: In clinical practice, patients who meet trial criteria and undergo LAAO experience a lower risk of ischemic stroke, a similar risk of hemorrhagic stroke, and a higher risk of death after implant versus LAAO trial patients. (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation [PROTECT-AF], NCT00129545; Evaluation of the WATCHMAN Left Atrial Appendage [LAA] Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy [PREVAIL], NCT01182441).
Authors: John C Messenger; Kalon K L Ho; Christopher H Young; Lara E Slattery; Jasmine C Draoui; Jeptha P Curtis; Gregory J Dehmer; Frederick L Grover; Michael J Mirro; Matthew R Reynolds; Ivan C Rokos; John A Spertus; Tracy Y Wang; Stuart A Winston; John S Rumsfeld; Frederick A Masoudi Journal: J Am Coll Cardiol Date: 2012-09-19 Impact factor: 24.094
Authors: David R Holmes; Vivek Y Reddy; Nicole T Gordon; David Delurgio; Shephal K Doshi; Amish J Desai; James E Stone; Saibal Kar Journal: J Am Coll Cardiol Date: 2019-12-10 Impact factor: 24.094
Authors: Srinivas R Dukkipati; Saibal Kar; David R Holmes; Shephal K Doshi; Vijendra Swarup; Douglas N Gibson; Brijeshwar Maini; Nicole T Gordon; Michael L Main; Vivek Y Reddy Journal: Circulation Date: 2018-08-28 Impact factor: 29.690
Authors: David R Holmes; Saibal Kar; Matthew J Price; Brian Whisenant; Horst Sievert; Shephal K Doshi; Kenneth Huber; Vivek Y Reddy Journal: J Am Coll Cardiol Date: 2014-07-08 Impact factor: 24.094
Authors: Sana M Al-Khatib; Anne Hellkamp; Gust H Bardy; Stephen Hammill; W Jackson Hall; Daniel B Mark; Kevin J Anstrom; Jeptha Curtis; Hussein Al-Khalidi; Lesley H Curtis; Paul Heidenreich; Eric D Peterson; Gillian Sanders; Nancy Clapp-Channing; Kerry L Lee; Arthur J Moss Journal: JAMA Date: 2013-01-02 Impact factor: 56.272
Authors: David R Holmes; Vivek Y Reddy; Zoltan G Turi; Shephal K Doshi; Horst Sievert; Maurice Buchbinder; Christopher M Mullin; Peter Sick Journal: Lancet Date: 2009-08-15 Impact factor: 79.321
Authors: Vivek Y Reddy; Shephal K Doshi; Saibal Kar; Douglas N Gibson; Matthew J Price; Kenneth Huber; Rodney P Horton; Maurice Buchbinder; Petr Neuzil; Nicole T Gordon; David R Holmes Journal: J Am Coll Cardiol Date: 2017-11-04 Impact factor: 24.094
Authors: Lucas V Boersma; Hueseyin Ince; Stephan Kische; Evgeny Pokushalov; Thomas Schmitz; Boris Schmidt; Tommaso Gori; Felix Meincke; Alexey Vladimir Protopopov; Timothy Betts; David Foley; Horst Sievert; Patrizio Mazzone; Tom De Potter; Elisa Vireca; Kenneth Stein; Martin W Bergmann Journal: Heart Rhythm Date: 2017-05-31 Impact factor: 6.343
Authors: James V Freeman; Paul Varosy; Matthew J Price; David Slotwiner; Fred M Kusumoto; Chidambaram Rammohan; Clifford J Kavinsky; Zoltan G Turi; Joseph Akar; Cristina Koutras; Jeptha P Curtis; Frederick A Masoudi Journal: J Am Coll Cardiol Date: 2020-04-07 Impact factor: 24.094